PE-22-28 is a synthetic peptide derived from spadin, a natural peptide that originates from the pro-peptide of sortilin. It is primarily researched for its rapid-acting antidepressant effects and its ability to stimulate neurogenesis (the birth of new neurons). Unlike traditional antidepressants, which can take weeks to work, PE-22-28 has shown therapeutic activity in animal models in as little as four days.

1. Key Mechanisms of Action

PE-22-28 works through a unique pathway compared to standard SSRIs or SNRIs:

• TREK-1 Channel Inhibition: Its primary role is blocking TREK-1 (a two-pore domain potassium channel). These channels normally act as a “brake” on neuronal excitability. By blocking them, PE-22-28 allows neurons to fire more easily, particularly in the hippocampus and prefrontal cortex.
• BDNF Mimicry: It acts as a “BDNF mimetic,” mimicking the effects of Brain-Derived Neurotrophic Factor. This triggers the PI3K/Akt and MAPK/ERK pathways, which are critical for cell survival and synaptic plasticity.
• Rapid Neurogenesis: Data suggests it promotes the proliferation of new neurons in the dentate gyrus of the hippocampus much faster than traditional pharmaceuticals.